Navigation Links
CareFusion Reports First Quarter Fiscal 2012 Results
Date:11/7/2011

with the FDA and our failure to comply with the requirements of the amended consent decree may have an adverse effect on our business; and our success depends on our key personnel, and the loss of key personnel or the transition of key personnel, including our chief executive officer, could disrupt our business. The CareFusion news release and the information contained herein reflect management's views as of Nov. 7, 2011. Except to the limited extent required by applicable law, CareFusion undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.CAREFUSION CORPORATIONCONDENSED CONSOLIDATED STATEMENTS OF INCOME(UNAUDITED)Quarter Ended September 30,(in millions, except per share amounts)20112010Revenue

$

844

$

811Cost of Products Sold417398Gross Margin427413Selling, General and Administrative Expenses273272Research and Development Expenses3940Restructuring and Acquisition Integration Charges722Operating Income10879Interest Expense and Other, Net 2523Income Before Income Tax8356Provision for Income Tax1620Income from Continuing Operations6736Income from Discontinued Operations, Net of Tax-2Net Income

$

67

$

38Per Share Amounts:(1)Basic Earnings per Common Share:Continuing Operations

$

0.30

$

0.17Discontinued Operations

$

-

$

0.01Basic Earnings per Common Share

$

0.30

$

0.17Diluted Earnings per Common Share:Continuing Operations

$

0.30

$

0.17Discontinued Operations

$

-

$

0.01Diluted Earnings per Common Share

$

0.30

$

0.17Weighted-Average Number of Common Shares Outstanding:Basic223.8222.1Diluted226.3223.9____________1Earnings per share calculations are performed separately for each component presented.  Therefore, the sum of the per share components from th
'/>"/>

SOURCE CareFusion
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. ERT Closes the Acquisition of the Research Services Division of CareFusion Corporation
2. Sequenom, Inc. Reports Financial Results for the Third Quarter of 2011
3. InterMune Reports Third Quarter 2011 Financial Results and Business Highlights
4. Cumberland Pharmaceuticals Reports Third Quarter 2011 Financial Results
5. Optimer Pharmaceuticals Reports Third Quarter 2011 Financial Results
6. Caliper Life Sciences Reports Third Quarter 2011 Results
7. Neurocrine Biosciences Reports Third Quarter 2011 Results
8. United Therapeutics Corporation Reports Third Quarter 2011 Financial Results
9. Sangamo BioSciences Reports Third Quarter 2011 Financial Results
10. Cell Therapeutics, Inc. (CTI) Reports Third Quarter Financial Results and Milestones
11. ReportsnReports: Depression Therapeutics Market to Reach $10.9 Billion by 2018
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... 2013  MacroGenics, Inc. today announced that an ... an Fc-modified chimeric monoclonal antibody (MAb), in patients ... will be presented at the 2013 Annual Meeting ... the Developmental Therapeutics - Immunotherapy Oral Abstract Session ... PM.  The presentation will describe the results of ...
(Date:5/21/2013)... -- Personal Genome Diagnostics Inc. (PGDx), today announced that ... in genomic analysis of defined cancer subtypes to ... Medicines.  PGDx is an innovator in conducting patient-specific ... and Blueprint Medicines is an expert in developing ... patient population. "This collaboration brings together ...
(Date:5/21/2013)... May 21, 2013 Revolutionary Science, the ... colony counter, announced today that they have expanded their ... , the IncuCount, IntelliCount, InCount and ImpressCount. These ... are especially useful in food microbiology and pharmaceutical manufacturing. ... updated look. A bright white enclosure with jet ...
(Date:5/21/2013)... Inflamax scientists worked closely with internationally ... the study, which will provide critical insight into ... in the study of allergy treatments, the Environmental ... models. Although both the models are well recognized ... direct comparison between the allergic responses evoked by ...
Breaking Biology Technology:MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3Personal Genome Diagnostics And Blueprint Medicines Form Collaboration to Identify Novel Kinase Targets 2Personal Genome Diagnostics And Blueprint Medicines Form Collaboration to Identify Novel Kinase Targets 3Revolutionary Science Announces New Automatic and Manual Colony Counting Products 2Inflamax Research selected by the Immune Tolerance Network and the National Institutes of Health to conduct a landmark clinical study on the underlying mechanisms of allergic inflammation. 2
... trial indicate statistically significant reduction in recurrences ... ... JAMAICA PLAIN, Mass., Nov. 3 /PRNewswire-FirstCall/,-- Medarex, Inc. (Nasdaq: MEDX ... Medical School (UMMS) today,announced that a Phase 2 trial of an ...
... Cepheid (Nasdaq:,CPHD) today announced that it ... Stretton Scientific Limited, a privately held distributor ... in,Stretton, England. Stretton Scientific currently distributes Cepheid,s,SmartCycler(R) ... products, to,a broad group of medical customers ...
... financial guidance through second quarter of 2009 - ... - Conference ... BRANFORD, Conn., Nov. 3 CuraGen Corporation,(Nasdaq: CRGN ), today ... the three month period ended September 30, 2008, CuraGen,utilized $3.6 million ...
Cached Biology Technology:Medarex and Massachusetts Biologic Laboratories Announce Primary Objective Achieved in Phase 2 Trial of Monoclonal Antibody Combination for the Treatment of Clostridium difficile Associated Diarrhea (CDAD) 2Medarex and Massachusetts Biologic Laboratories Announce Primary Objective Achieved in Phase 2 Trial of Monoclonal Antibody Combination for the Treatment of Clostridium difficile Associated Diarrhea (CDAD) 3Medarex and Massachusetts Biologic Laboratories Announce Primary Objective Achieved in Phase 2 Trial of Monoclonal Antibody Combination for the Treatment of Clostridium difficile Associated Diarrhea (CDAD) 4Medarex and Massachusetts Biologic Laboratories Announce Primary Objective Achieved in Phase 2 Trial of Monoclonal Antibody Combination for the Treatment of Clostridium difficile Associated Diarrhea (CDAD) 5Medarex and Massachusetts Biologic Laboratories Announce Primary Objective Achieved in Phase 2 Trial of Monoclonal Antibody Combination for the Treatment of Clostridium difficile Associated Diarrhea (CDAD) 6Cepheid Accelerates Direct Sales Channel in UK With Pending Acquisition of Medical Distributor Stretton Scientific 2Cepheid Accelerates Direct Sales Channel in UK With Pending Acquisition of Medical Distributor Stretton Scientific 3CuraGen Reports Third Quarter 2008 Financial Results 2CuraGen Reports Third Quarter 2008 Financial Results 3CuraGen Reports Third Quarter 2008 Financial Results 4CuraGen Reports Third Quarter 2008 Financial Results 5CuraGen Reports Third Quarter 2008 Financial Results 6
(Date:5/21/2013)... most deadly when they metastasize and spread tumors throughout ... becomes very difficult for doctors to locate and treat ... the University of Missouri have found a way to ... they may be in the body. Michael Lewis, an ... Veterinary Medicine, says being able to target secondary tumors ...
(Date:5/21/2013)... in pharmacies and health stores, phosphatidylserine is a ... soy. Proven to improve cognition and slow memory ... experiencing memory impairment. Now a team headed by ... Tel Aviv University,s Department of Human Molecular ... improves the functioning of genes involved in degenerative ...
(Date:5/21/2013)... in shape is an uphill battle? Try staying fit ... weightlessness withers muscle and bone. , That,s the challenge ... with a new three-year, $1.2 million grant from NASA. ... during multiyear exploratory missions. , "You could give astronauts ... can,t get them to stick to it, it isn,t ...
Breaking Biology News(10 mins):MU researchers develop radioactive nanoparticles that target cancer cells 2Common food supplement fights degenerative brain disorders 2Fueling fitness on the final frontier 2
... birds often choose their mates based on fancy feathers. ... likely to follow their noses to the right mate. ... Harvard researcher Katherine McAuliffe, whose review of evidence for ... issue of The Quarterly Review of Biology . ...
... that belongs to the oldest living family of jawed vertebrates, ... discovery, published in the March 2009 issue of Genome ... evolved in early vertebrates over the last 450 million years ... vertebrate like the elephant shark had the potential for color ...
... a novel regulator of p53, an important protein that safeguards ... March 17, 2009 issue of the journal Genes & ... this microRNA keeps the level of p53 low to avoid ... damaged, the microRNA level is reduced to allow an increase ...
Cached Biology News:Female mammals follow their noses to the right mates 2Elephant shark genome sequence leads to discovery of color perception in deep-sea fish 2Regulatory molecule for tumor formation or suppression identified by Singapore, US researchers 2
... 9 oligodeoxynucleotides are random ... at the 5' end ... Fluor dyes and they ... microarray spot morphology, hybridization ...
Mycoplasma tested...
The Spheroplast Kit contains qualified reagents for the preparation of yeast spheroplasts. The reagents have been optimized for use with Pichia pastoris and are guaranteed to generate 70% spheroplast...
... Our fastest automated perfusion system. For ... perfusion, physiology, biophysics, electrochemistry, or general ... with 1.5-4 millisecond accuracy Run ... Microprocessor-based for accuracy and flexibility ...
Biology Products: